Hatchtech Pty Ltd is a specialty pharmaceutical company located in Melbourne, Australia. The Company is developing Xeglyze™ Lotion, a proprietary next generation head lice treatment.
Xeglyze™ is a topical lotion containing an inhibitor of metalloproteinases known to impede a number of physiological processes involved in all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established its mode of action, and preclinical and clinical studies have evaluated the efficacy and safety of Xeglyze™.
Xeglyze™ Lotion recently successfully completed two Phase 3 clinical studies conducted under a Special Protocol Agreement with the U.S. Food and Drug Administration (FDA). Hatchtech plans to submit a New Drug Application to the FDA in 2015.
The Company was originally founded through programs that originated at the University of Melbourne in Australia. Hatchtech has a comprehensive patent estate for Xeglyze™ Lotion including granted U.S. and EU patents, and several pending patent applications.
Hatchtech is securely financed by a consortium of specialist venture capitalists and sophisticated investors.
Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results
Dec 11, 2013 Hatchtech Receives SPA and Announces Patent Grants